Acute myeloid leukemia in children: Current status and future directions

Pediatrics International - Tập 58 Số 2 - Trang 71-80 - 2016
Takashi Taga1, Daisuke Tomizawa2, Hiroyuki Takahashi3, Souichi Adachi4
1Department of Pediatrics, Shiga University of Medical Science, Otsu, Japan
2Division of Leukemia and Lymphoma, Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan
3Department of Pediatrics, Toho University, Tokyo, Japan
4Human Health Sciences, Kyoto University, Kyoto, Japan

Tóm tắt

AbstractAcute myeloid leukemia (AML) accounts for 25% of pediatric leukemia and affects approximately 180 patients annually in Japan. The treatment outcome for pediatric AML has improved through advances in chemotherapy, hematopoietic stem cell transplantation (HSCT), supportive care, and optimal risk stratification. Currently, clinical pediatric AML studies are conducted separately according to the AML subtypes: de novo AML, acute promyelocytic leukemia (APL), and myeloid leukemia with Down syndrome (ML‐DS). Children with de novo AML are treated mainly with anthracyclines and cytarabine, in some cases with HSCT, and the overall survival (OS) rate now approaches 70%. Children with APL are treated with an all‐trans retinoic acid (ATRA)‐combined regimen with an 80–90% OS. Children with ML‐DS are treated with a less intensive regimen compared with non‐DS patients, and the OS is approximately 80%. HSCT in first remission is restricted to children with high‐risk de novo AML only. To further improve outcomes, it will be necessary to combine more accurate risk stratification strategies using molecular genetic analysis with assessment of minimum residual disease, and the introduction of new drugs in international collaborative clinical trials.

Từ khóa


Tài liệu tham khảo

10.1007/s12185-013-1364-2

10.1002/pbc.20944

10.1200/JCO.2008.18.7948

Taga T, 2010, A morphology‐based approach for the treatment of children with acute myeloid leukaemia: A report from the Japanese Children's Cancer and Leukemia Study Group AML 9805 Study, Jpn J. Pediatr. Hematol., 24, 283

10.1038/leu.2013.153

10.1007/s12185-013-1429-2

10.1111/bjh.12993

10.1016/S1470-2045(10)70090-5

10.1200/JCO.2010.30.6829

10.1111/j.1365-2141.2011.08851.x

10.1182/blood-2013-02-484097

10.1182/blood-2013-03-491621

10.1200/JCO.2014.55.3628

10.1182/blood.V58.6.1203.1203

10.1182/blood.V89.7.2311

10.1182/blood-2008-10-184747

10.1038/leu.2008.313

10.1182/blood-2005-08-3408

10.1182/blood-2009-09-241075

10.1056/NEJM199410063311402

10.1200/JCO.2004.07.012

10.1182/blood-2011-07-364661

10.1038/sj.leu.2403925

10.1182/blood.V97.1.56

10.1182/blood-2007-04-084293

10.1038/sj.leu.2403932

10.1046/j.1365-2141.1998.00677.x

10.1038/sj.leu.2401254

10.1200/JCO.2003.11.066

10.1200/JCO.2003.06.128

10.1111/j.1365-2141.2006.06419.x

10.1038/leu.2010.127

10.1002/pbc.22612

10.1200/JCO.2012.43.7384

10.1007/s12185-014-1616-9

10.1200/JCO.2011.41.5323

10.1038/leu.2010.153

10.1182/blood-2012-02-408336

10.1056/NEJMoa0904544

10.1182/blood-2010-03-273243

10.1182/blood.V87.5.1710.1710

10.1182/blood.V88.8.2841.bloodjournal8882841

10.1002/cncr.21543

10.1056/NEJMoa1010222

10.1182/blood-2004-08-3218

10.1182/blood-2010-07-296392

10.1200/JCO.2008.18.8706

10.1200/JCO.2011.34.7427

10.1200/JCO.2010.30.7231

10.1177/2040620715571077

10.1016/j.leukres.2014.12.014

10.1038/leu.2014.124

10.1182/blood-2013-09-527044

10.1038/leu.2014.62

10.1111/j.1365-2141.1976.tb03563.x

10.1182/blood-2009-03-209262

10.1038/sj.leu.2403031

10.1182/blood-2007-07-102798

10.1182/blood.V99.3.759

10.1634/theoncologist.10-10-806

10.1111/j.1365-2141.2010.08332.x

10.1182/blood-2010-01-266007

Botton S, 2004, Outcome of childhood acute promyelocytic leukemia with all‐trans retinoic acid and chemotherapy, J. Clin. Oncol., 1402

10.1182/blood-2010-08-302950

10.1200/JCO.2005.01.3359

10.1111/j.1365-2141.2010.08107.x

10.1056/NEJMoa1300874

10.1038/sj.leu.2403135

10.1038/sj.leu.2404501

Diverio D, 1998, Early detection of relapse by prospective reverse transcriptase‐polymerase chain reaction analysis of the PML/RARa fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA‐AIEOP multicenter “AIDA” trial, Blood, 92, 784, 10.1182/blood.V92.3.784

10.1182/blood.V93.12.4131

10.1038/sj.leu.2403814

10.1007/s00277-005-0045-5

10.1111/j.1365-2141.2005.05906.x

10.1200/JCO.2003.08.060

10.1002/cncr.27484

10.1111/j.1365-2141.2006.06097.x

10.1200/JCO.2007.12.3687

10.1002/pbc.22943

Taga T, 2015, Preserved High Probability of Overall Survival with Significant Reduction of Chemotherapy for Myeloid Leukemia in Down Syndrome: A Nationwide Prospective Study in Japan, Pediatr Blood & Cancer.

Taub JW, 2014, New prognostic parameter in down syndrome acute myeloid leukemia (DS‐AML): Results of the Children's Oncology Group (COG) Phase III AAML0431 Trial, Blood, 124, 278, 10.1182/blood.V124.21.278.278

10.1182/blood-2012-03-414755

10.1002/pbc.25081

10.1016/j.cell.2012.06.032

10.1038/leu.2013.264

Thông tin
Thông tin xuất bản

Pediatrics International

Tập 58 Số 2

71-80

Thông tin tác giả